| 吴娟,王丹,张前进,等.膀胱癌 100例血清 Zeste基因增强子同源物 2和信号传导蛋白 3表达水平及诊断价值分析[J].安徽医药,2024,28(10):2035-2038. |
| 膀胱癌 100例血清 Zeste基因增强子同源物 2和信号传导蛋白 3表达水平及诊断价值分析 |
| Expression and diagnostic value analysis of enhancer of zeste homolog 2 and signal transduction protein 3 in 100 cases of bladder cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2024.10.026 |
| 中文关键词: 膀胱肿瘤 Zeste基因增强子同源物 2 信号传导蛋白 3 诊断价值 表达水平 |
| 英文关键词: Urinary bladder neoplasms Enhancer of Zeste homolog 2 Signal transduction protein 3 Diagnostic value Expression level |
| 基金项目:宿迁市科技计划项目( K202105) |
|
| 摘要点击次数: 788 |
| 全文下载次数: 461 |
| 中文摘要: |
| 目的探讨膀胱癌病人血清 Zeste基因增强子同源物 2(EZH2)和信号传导蛋白 3(SMAD3)表达水平及临床意义。方纳入江苏省人民医院宿迁医院于 2021年 1月至 2022年 12月收治的膀胱癌病人进行研究( 100例)另选取同期于该院就诊法的泌尿系统良性疾病病人作为良性疾病组( 93例)以及健康体检者作为对照( 100例)。采用 Pearson相关，性分析法分析膀胱癌病人血清中 EZH2和 SMAD3表达水平的相关性；采用 logistic多因素回归分析法分析膀胱癌发生的影响因素；采用 ROC曲线分析 EZH2和 SMAD3对膀胱癌的诊断效能。结果膀胱癌病人血清中 EZH2(101.34±15.09)ng/L和 SMAD3(226.53±25.94)ng/L表达水平均高于良性疾病组( 85.96±11.23)ng/L、(203.11±22.18)ng/L和对照组( 83.91±9.14)ng/L、(198.03±20.30)ng/L(均 P<0.001)；膀胱癌病人血清 EZH2和 SMAD3表达水平呈正相关( r=0.72，P<0.001)；膀胱癌组年龄 ≥60岁( 74/187)、有吸烟史的病人(76/166)所占比例均高于良性疾病组( 65/187、55/166)及对照组( 48/187、35/166)(均 P<0.05)；年龄、吸烟史、 EZH2、SMAD3为发生膀胱癌的危险因素( P<0.05)；以良性疾病组为对照，血清 EZH2和 SMAD3单独检测诊断膀胱癌的曲线下面积( AUC)分别为 0.78、0.78，二者联合检测的 AUC为 0.85，优于各自单独检测( Z二者联合 -EZH2=2.81、Z二者联合 -SMAD3=2.68，P=0.009、0.007)。结论血清 EZH2和 SMAD3与膀胱癌的发生有关，二者联合对膀胱癌具有一定的诊断价值。 |
| 英文摘要: |
| Objective To investigate the expression levels of enhancer of Zeste homolog 2 (EZH2) and signal transduction protein 3(SMAD3) in serum of patients with bladder cancer and their clinical significance.Methods The study included 100 patients with bladder cancer admitted to Jiangsu Provincial People's Hospital Suqian Hospital from January 2021 to December 2022. In addition, patients with benign diseases of the urinary system who visited our hospital at the same time were selected as the benign disease group (93cases) and health check-up participants as controls (100 cases). Pearson correlation analysis was used to analyze the correlation between the expression levels of EZH2 and SMAD3 in the serum of bladder cancer patients; Logistic regression analysis was used to analyze the influencing factors of bladder cancer; ROC curve was used to analyze the diagnostic efficacy of EZH2 and SMAD3 in bladdercancer.Results The expression levels of EZH2 (101.34±15.09)ng/L and SMAD3 (226.53±25.94)ng/L in the bladder cancer group weresignificantly higher than those in the benign disease group (85.96±11.23)ng/L, (203.11±22.18)ng/L and the control group (83.91±9.14)ng/L, (198.03±20.30)ng/L(P<0.001); the expression levels of EZH2 and SMAD3 in serum of bladder cancer patients were positively correlated (r=0.72, P<0.001); the proportions of patients with age ≥ 60 years (74/187) and smoking history (76/166) in bladder cancer groupwere higher than those in benign disease group (65/187, 55/166) and control group (48/187, 35/166) (P<0.05); age, smoking history, EZH2, and SMAD3 were risk factors for bladder cancer (P<0.05); Using the benign disease group as a control, the AUC of serum EZH2and SMAD3 for diagnosis of bladder cancer was 0.78 and 0.78, respectively, and the AUC of the combination of the two was 0.85, whichwas superior to individual testing (Z combined detection-EZH2=2.81, Zcombined detection-SMAD3=2.68, P=0.009, 0.007). Conclusion Serum EZH2 and SMAD3 are related to the occurrence of bladder cancer, and their combination has certain diagnostic value for bladder cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
